Loading
Life sciences · Journal article
iScience · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Immune checkpoint inhibitors (ICIs) improve cancer outcomes but can cause immune-related adverse events (irAEs) that compromise treatment. Using FAERS real-world data, we developed a two-layer network algorithm to identify irAE-associated lncRNAs (irAEsLncs) across 18 cancer types. The irAEsLnc network showed organ-specific patterns and cancer-specific irAE susceptibility, while irAEsLncs were associated with immune infiltration, inflammatory responses, immune activation, and checkpoint molecules. Single-cell analysis of ICI-induced colitis linked irAEsLncs to inflammatory macrophage and T cell states and metabolic reprogramming. irAEsLnc-derived signatures independently predicted prognosis and responses to targeted therapy and immunotherapy, with ALAL-1/CD80/MEF2C predicting ICI efficacy in lung adenocarcinoma. Knockdown of ALAL-1 and SEC61G-DT suppressed tumor cell proliferation, migration, invasion, and macrophage-mediated inflammation. These findings connect irAE-associated lncRNAs with toxicity and antitumor immunity and support their potential as biomarkers for treatment stratification.